metastatic lung tumor
Conditions
Interventions
None listed
Sponsors
Keio University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients who have undergone surgery or undergone bronchoscopy, thoracoscopy, mediastinoscopy, percutaneous needle biopsy, thoracentesis, peritoneal tap, pericardiocentesis, lymph node biopsy, or nasal ablation for the treatment or diagnosis of metastatic lung tumor at Department of Respiratory Surgery and Department of Respiratory Medicine, Keio University Hospital. 2) Informed consent has been obtained in writing from the patient for participation in the study. 3) Informed consent has been obtained from a surrogate if the patient (adult) is incapable of consenting.
Exclusion criteria
Exclusion criteria: Patients who are deemed by the principal investigator or subinvestigator to be inappropriate to conduct this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Organoid establishment efficiency by primary tumor 1) Organoid establishment rate: Percentage of patients with metastatic lung tumor organoids cultured for a minimum of 6 spitzes per primary tumor, using metastatic lung tumor organoid cultures as the denominator. 2) Organoid establishment period: The period from the start date of metastatic lung tumor organoid culture to the date when at least 6 spits of organoids were frozen and cultured for each primary tumor. Drug sensitivity of organoids per primary tumor Drug efficacy evaluation of cytotoxic anticancer drugs such as platinum (cisplatin), antimetabolites (fluorouracil), and microvascular inhibitors (docetaxel, paclitaxel), and functional analysis of therapeutic target molecules will be performed in vitro or in vivo. | — |
Countries
Japan
Contacts
Public ContactSeiji Omura
Keio University Hospital Surgery (respiratory)
Outcome results
None listed